2-((1-(2-(Azepan-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-(4-butylphenyl)acetamide

Catalog No. :
ACOWGJ470
CAS No. :
878059-02-0
Molecular Formula :
C28H35N3O4S
Molecular Weight :
509.67

IUPAC Name:2-((1-(2-(azepan-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-(4-butylphenyl)acetamide

2-((1-(2-(Azepan-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-(4-butylphenyl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-((1-(2-(Azepan-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-(4-butylphenyl)acetamide
IUPAC Name2-((1-(2-(azepan-1-yl)-2-oxoethyl)-1H-indol-3-yl)sulfonyl)-N-(4-butylphenyl)acetamide
Molecular FormulaC28H35N3O4S
Molecular Weight509.67
SMILESO=C(NC1=CC=C(CCCC)C=C1)CS(=O)(C2=CN(CC(N3CCCCCC3)=O)C4=C2C=CC=C4)=O
InChI KeyNXVJRMREGOOEAJ-UHFFFAOYSA-N
SynonymAcetamide, N-(4-butylphenyl)-2-[[1-[2-(hexahydro-1H-azepin-1-yl)-2-oxoethyl]-1H-indol-3-yl]sulfonyl]-
CAS No.878059-02-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACOWGJ470 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBAFP675 route compound structure diagram
    ACBAFP675104-13-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOWGJ470 route product structure diagram
    ACOWGJ470878059-02-0
Inquiry

2. ACOWGJ470 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOWGJ470 route product structure diagram
    ACOWGJ470878059-02-0
Inquiry

Comments (0)